FDA-cleared K260714

MammoScreen® (5)

Therapixel

Authorized purpose: Flags calcifications, masses, asymmetries and architectural distortions on compatible FFDM or DBT screening examinations; management must not be based solely on MammoScreen output.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-06-26
FDA-cleared K241831

Transpara (2.1.0)

ScreenPoint Medical B.V.

Authorized purpose: Transpara 2.1.0 is a concurrent reading aid for physicians interpreting screening full-field digital mammography and digital breast tomosynthesis, providing region and examination scores to support review of suspicious breast findings.

Modality
Mammography/DBT
Anatomy
Breast; regions suspicious for cancer on screening mammography and digital breast tomosynthesis
Decision
2024-11-25
FDA-cleared K220105

Saige-Dx

DeepHealth, Inc.

Concurrent-reading software for screening DBT mammography that highlights suspected soft-tissue lesions and calcifications for physician review.

Modality
Mammography/DBT
Anatomy
Breast; screening DBT findings and calcifications
Decision
2022-05-12
FDA-cleared K161201

ClearRead CT

RIVERAIN TECHNOLOGIES, LLC

Authorized purpose: ClearRead CT is a post-processing adjunct for detecting pulmonary nodules on chest CT in an asymptomatic population; it generates a secondary vessel-suppressed lung CT with CADe marks and region descriptors and must be reviewed with the original CT series.

Modality
CT/CTA
Anatomy
Chest/lungs
Decision
2016-09-09